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Abstract 
Background: Breakdown of renal endothelial, tubular and glomerular matrix collagen plays a major role in acute 
kidney injury (AKI) development. Such collagen breakdown releases endostatin into the circulation. The aim of this 
study was to compare the AKI predictive value of plasma endostatin with two previously suggested biomarkers of AKI, 
cystatin C and neutrophil gelatinase‑associated lipocalin (NGAL).
Methods: We studied 93 patients without kidney disease who had a first plasma sample obtained within 48 h of ICU 
admission. We identified risk factors for AKI within the population and designed a predictive model. The individual 
ability and net contribution of endostatin, cystatin C and NGAL to predict AKI were evaluated by the area under the 
receiver operating characteristics curve (AUC), likelihood‑ratio test, net reclassification improvement (NRI) and inte‑
grated discrimination improvement (IDI).
Results: In total, 21 (23 %) patients experienced AKI within 72 h. A three‑parameter model (age, illness severity score 
and early oliguria) predicted AKI with an AUC of 0.759 (95 % CI 0.646–0.872). Adding endostatin to the predictive 
model significantly (P = 0.04) improved the AUC to 0.839 (95 % CI 0.752–0.925). In addition, endostatin significantly 
improved risk prediction using the likelihood‑ratio test (P = 0.005), NRI analysis (0.27; P = 0.04) and IDI analysis (0.07; 
P = 0.04). In contrast, adding cystatin C or NGAL to the three‑parameter model did not improve risk prediction in any 
of the four analyses.
Conclusions: In this cohort of critically ill patients, plasma endostatin improved AKI prediction based on clinical risk 
factors, while cystatin C and NGAL did not.
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Background
Acute kidney injury (AKI) is common in the critically ill 
and associated with a high mortality rate [1]. Biomarkers 
may allow earlier detection of patients at risk of AKI and 
enable earlier intervention. Endostatin, the C-terminal 
fragment of collagen XVIII, is released into the circula-
tion as a consequence of accelerated turnover of collagen 
XVIII in the basement membranes of the renal tubular 
epithelium, Bowman’s capsule, mesangium and renal 
capillaries, and may be one such biomarker [2].
In animal AKI models, upregulated renal endostatin 
expression preceded deteriorating kidney function by 
several hours [3, 4]. In addition, elevated serum endosta-
tin has been associated with the degree of renal dys-
function in elderly patients and independently predicts 
the subsequent development of chronic kidney disease 
(CKD) in this population [5]. Endostatin has also been 
associated with mortality in several patient groups [6–8]. 
However, the potential of endostatin to identify critically 
ill patients at a higher risk of AKI remains unexplored.
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Accordingly, we conducted a prospective, exploratory 
observational study to investigate the value of plasma 
endostatin as an early biomarker of AKI by comparing 
it with traditional clinical assessments of renal function 
and with plasma neutrophil gelatinase-associated lipoca-
lin (NGAL) and plasma cystatin C. We hypothesized that, 
in patients with normal renal function on ICU admis-
sion, plasma endostatin levels would be higher among 
those patients who subsequently develop AKI compared 
with those who do not. In addition, we hypothesized that 
admission plasma endostatin would improve the AKI 
predictive ability of a clinical risk model.
Methods
This study was approved by the regional ethical review 
board in Stockholm and has therefore been performed 
in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and its later amendments. 
Written informed consent was obtained from patients or 
their next of kin.
Patient selection and operational definitions
We screened patients admitted to the general intensive 
care unit (ICU) at the Karolinska University Hospital, 
Solna, Sweden, from August 2007 to November 2010. 
We enrolled patients with an expected length of stay of 
more than 24 h and an estimated glomerular filtration rate 
(eGFR) of more than 60 mL/min/1.73 m2 (modification of 
diet in renal disease [MDRD] equation) on ICU admission.
We defined AKI as a ≥50 % increase in plasma creati-
nine from baseline or an increase in plasma creatinine 
by ≥26.5 µmol/L within 48 h and/or a urine output less 
than 0.5 mL/kg/h for at least 6 consecutive hours accord-
ing to the Kidney Disease: Improving Global Outcomes 
(KDIGO) criteria [9]. We used the lowest creatinine level 
obtained within 3 months before ICU admission as base-
line for the KDIGO classification. Missing baseline creati-
nine was imputed using the MDRD formula and an eGFR 
of 75 mL/min/1.73 m2 [9]. We decided a priori to exclude 
patients having their first study sample obtained >48  h 
after ICU admission and patients with AKI on the day of 
their first study sample collection. Our primary outcome 
was development of AKI within 72 h of first study sample 
collection. Accordingly, we recorded AKI status until a 
maximum of 5 days following ICU admission.
We defined the systemic inflammatory response syn-
drome (SIRS) using three or more SIRS criteria [10]. 
Sepsis was defined as a suspected or confirmed infection 
together with SIRS.
Plasma sampling and biomarker analyses
We collected blood samples on study inclusion and twice 
daily thereafter until ICU discharge or start of renal 
replacement therapy. After centrifugation at 2000  rpm 
at 4 °C for 10 min, the supernatant plasma was stored at 
−80 °C.
Endostatin and NGAL were analyzed during 2013 
using a commercially available enzyme-linked immu-
nosorbent assay (ELISA) kit [DY1098 (endostatin) and 
DY1757 (NGAL), R&D Systems, Minneapolis, MN]. The 
assays had a total coefficient of variation (CV) of approxi-
mately 6  %. Cystatin C was measured with a particle-
enhanced turbidimetric immunoassay on the Architect 
Ci8200 analyzer (Abbott Laboratories, Abbott Park, IL) 
with cystatin C reagents from Gentian (Moss, Norway).
Statistical analysis
Data were analyzed using STATA® version 11.2 software 
(Stata Corporation, College Station, TX, USA). Data are 
presented as medians and interquartile ranges (IQR) or 
as numbers and percentages. The Mann–Whitney test 
and Fisher’s exact test were used to test for differences 
between groups. The change over time for endostatin 
was tested by a repeated-measure analysis of variance 
(ANOVA). To compare the change over time between 
groups (AKI versus no AKI), we introduced an interac-
tion variable between group and time to the ANOVA 
model. We assessed correlation using Spearman’s rank 
correlation coefficient (rho). The association of clinical 
variables with AKI development was assessed by multi-
variate logistic regression analysis. The following clinical 
predictor variables were considered: age, sex, acute phys-
iology and chronic health evaluation (APACHE) II score, 
baseline creatinine, delta creatinine, early oliguria (urine 
output <0.5 mL/kg/h for >2 h but <6 h), presence of SIRS, 
presence of sepsis and noradrenaline dose. Clinical pre-
dictor variables were included in the multivariate models 
if they were statistically significant at P < 0.10 in the uni-
variate analyses.
We assessed whether the addition of the measured 
biomarkers to the clinical model improved the predictive 
power for AKI by using the likelihood-ratio test. In addi-
tion, we calculated the area under the receiver operating 
characteristics curve (AUC) for the clinical model with 
and without inclusion of the measured biomarkers. The 
equality of AUCs was assessed by the method of DeLong 
et al. [11]. We described AUCs using the following val-
ues: 0.90–1.0 excellent, 0.80–0.89 good, 0.70–0.79 fair, 
0.60–0.69 poor and 0.50–0.59 no useful performance 
[12]. The contributions of the biomarkers to risk pre-
diction were further assessed by the net reclassification 
improvement (NRI) and the integrated discrimination 
improvement (IDI) methods. Log-transformed (base 10) 
biomarker values were used in the statistical analyses. 
Two-sided P values below 0.05 were considered statisti-
cally significant.
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Results
Study patients
We enrolled 138 patients with eGFR  >  60  mL/
min/1.73 m2 and an expected length of stay >24 h (Fig. 1). 
We excluded 16 patients who were enrolled after >48 h 
of ICU admission and 29 patients with AKI on the day of 
their first study sample. We therefore studied 786 plasma 
samples in 93 patients; of these, 21 [22.6 % (95 % CI 14.6–
32.4  %)] patients developed AKI within 72  h. Of the 21 
AKI patients, 16 [76.2 % (52.8–91.8 %)] developed stage 
1 AKI, 3 [14.3 % (3.0–36.3 %)] developed stage 2 AKI, 2 
[9.5 % (1.2–30.4 %)] developed stage 3 AKI and 2 [9.5 % 
(1.2–30.4 %)] received renal replacement therapy.
Compared to non-AKI patients, AKI patients were 
older and had greater illness severity on presentation 
and more comorbidities (Table  1) but did not have sig-
nificantly worse renal function at baseline. By 30  days 
after ICU admission, 4 (19 %) of 21 patients developing 
AKI had died compared to 8 (11  %) of the 72 non-AKI 
patients (P = 0.46).
Clinical renal characteristics at study inclusion
At inclusion, plasma creatinine levels (P = 0.20) and the 
changes in plasma creatinine from estimated or known 
baseline creatinine (P  =  0.07) were similar (Table  2). 
Nine AKI patients (42.9 %) had early oliguria at inclusion, 
compared to 6 (8.3  %) non-AKI patients (P  =  0.001). 
There was no difference in the prevalence of SIRS or sep-
sis at inclusion between groups (Table 2).
Biomarker characteristics at study inclusion
Plasma endostatin levels were significantly higher 
in patients who developed AKI (P  =  0.002; Table  2) 
and remained higher during the first four study days 
(P  =  0.01; Fig.  2). Inclusion cystatin C concentrations 
were also significantly greater in the AKI cohort at 
inclusion (P = 0.02; Table 2) and during the four study 
days (P  =  0.002; Additional file  1: Fig.  S1). However, 
we found no significant difference in plasma NGAL 
between the groups at inclusion (P  =  0.29; Table  2) 
or over time (P = 0.06; Additional file 1: Fig. S2). Sep-
tic patients, as compared to non-septic patients, had 
higher plasma NGAL at inclusion (P < 0.001), whereas 
endostatin (P  =  0.09) and cystatin C (P  =  0.08) lev-
els were similar in patients with and without sepsis 
(Fig.  3). We found a significant correlation between 
age and endostatin (Spearman’s rho 0.28, P  =  0.006) 
and between age and cystatin C (Spearman’s rho 0.50, 
P < 0.001) but not between age and NGAL (Spearman’s 
rho 0.13, P = 0.17).
Fig. 1 Selection of study patients
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Predicting the development of AKI
On univariate analysis, age, APACHE II score and early 
oliguria were associated with the development of AKI 
within 72 h and were included in a three-parameter clini-
cal risk prediction model (Additional file  1: Table  S1). 
This model predicted AKI with an AUC of 0.759 (95 % CI 
0.646–0.872; Table 3).
Endostatin alone predicted AKI with a similar AUC of 
0.726 (0.603–0.848). Its optimal cutoff value of 37 ng/mL 
predicted AKI with a sensitivity of 71 % and a specificity 
of 65 % (Additional file 1: Table S2).
The addition of endostatin significantly improved the 
clinical three-parameter regression model, as confirmed 
by the likelihood-ratio test (P = 0.005; Additional file 1: 
Table  S3). This endostatin-enhanced model was sig-
nificantly better at predicting subsequent AKI than the 
clinical model alone, with an AUC of 0.839 (95  % CI 
0.752–0.925; Table 3; Fig. 4), supported by both the net 
reclassification (P  =  0.04; Table  3) and the integrated 
discrimination improvement indices (P = 0.04; Table 3). 
Cystatin C and NGAL were both poorly individually pre-
dictive of subsequent AKI (Table  3). Furthermore, the 
addition of either cystatin C or NGAL to the clinical pre-
dictive model failed to achieve any significant improve-
ment in risk prediction (Table 3; Fig. 4; Additional file 1: 
Tables S4 and S5).
Sensitivity analysis
We repeated the risk prediction analyses after removing 
age from the clinical model since age is a component of 
the APACHE II score. Both APACHE II and early olig-
uria were associated with AKI in this bivariate model. 
Adding endostatin to the bivariate model improved AKI 
prediction on the likelihood-ratio test (P  <  0.001), the 
net reclassification improvement test (P = 0.02) and the 
integrated discrimination improvement test (P  =  0.01). 
In contrast, adding cystatin C or NGAL did not improve 
risk prediction based on the bivariate model in any of the 
analyses (Additional file 1: Tables S6–S9 and Additional 
file 1: Fig. S3–S5).
Table 1 Patient characteristics and outcomes






Age (years) 50 (28, 65) 66 (57, 71) 0.002
Female gender 22 (31 %) 5 (24 %) 0.79
APACHE II score 15 (11, 19) 19 (14, 24) 0.01
Body weight (kg) 78 (70, 90) 88 (79, 93) 0.06
Baseline creatinine (µmol/l) 82 (69, 91) 83 (71, 88) 0.69
True baseline creatinine available 52 (72 %) 12 (57 %) 0.28
Time admission–enrolled (h) 12 (5, 23) 8 (3, 14) 0.10
Time from first biomarker analysis to AKI diagnosis (days) N/A 1.0 (0.5, 1.5)
Comorbidity
 Diabetes 6 (8 %) 5 (24 %) 0.12
 Cardiovascular disease 20 (28 %) 11 (52 %) 0.06
 COPD/asthma 5 (7 %) 2 (10 %) 0.65
 Gastrointestinal/liver disease 2 (3 %) 3 (14 %) 0.07
 Any malignancy 11 (15 %) 3 (14 %) 1.0
Admission diagnosis
 Neurologic 4 (6 %) 1 (5 %) 0.03
 Respiratory 14 (19 %) 6 (29 %)
 Cardiovascular 2 (3 %) 5 (24 %)
 Trauma 37 (51 %) 7 (33 %)
 Gastrointestinal 3 (4 %) 1 (5 %)
 Sepsis 12 (17 %) 1 (5 %)
Outcome
 ICU length of stay, days 5 (3, 9) 4 (3, 8) 0.72
 ICU mortality 4 (6 %) 2 (10 %) 0.62
 30‑day mortality 8 (11 %) 4 (19 %) 0.46
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Discussion
Key findings
We conducted a prospective, exploratory study assessing 
the relationship between a novel potential AKI biomarker 
(plasma endostatin) and AKI in critically ill patients. In 
this cohort, we found that plasma endostatin levels were 
higher in patients who developed AKI than in those who 
did not and that elevated plasma endostatin levels were 
independently associated with an increased risk of AKI. 
Moreover, the addition of plasma endostatin to a clini-
cal prediction model significantly improved risk predic-
tion performance for subsequent AKI. Finally, plasma 
endostatin concentration achieved greater utility in the 
prediction of subsequent AKI than either plasma NGAL 
or plasma cystatin C concentration.
Relationship to previous studies
To our knowledge, this is the first investigation of plasma 
endostatin in critically ill humans as a predictor of AKI. 
However, in a cohort of elderly patients, serum endosta-
tin levels independently predicted the future develop-
ment of CKD [5]. In this population, endostatin also 
correlated strongly with eGFR. Moreover, up to fivefold 
higher endostatin levels have been observed in patients 
with CKD or ESRD [13, 14].
In the present study, inclusion endostatin levels were 
low and comparable to those observed in community-
based cohorts (the PIVUS and ULSAM cohorts) [5]. 
Compared to these cohorts, our patients were mark-
edly younger (median age 50–66  years versus a mean 
age >75 years in PIVUS and ULSAM) and did not have 
Table 2 Illness severity, organ function and inflammatory response at study inclusion
Values are reported as median (interquartile range) or as n (%)
a Urine output <0.5 mL/kg/h during >2 h but <6 h
No AKI (n = 72) AKI (n = 21) P value
Vasopressors and inotropes
 Noradrenaline dose (µg/kg/min) 0 (0, 0.03) 0.01 (0, 0.04) 0.43
 Adrenaline [n (%)] 0 (0) 1 (4.8 %) 0.23
 Dobutamine [n (%)] 1 (1.4 %) 3 (14.3 %) 0.04
Kidney function
 Plasma creatinine [µmol/l] 82 (69, 96) 91 (74, 93) 0.20
 Δ creatinine [%] 0 (−12, 18) 8 (1, 25) 0.07
 Early oliguriaa [n (%)] 6 (8.3 %) 9 (42.9 %) 0.001
 Furosemide dose, mg during previous 24 h 6 (0, 23) 0 (0, 35) 0.93
Lung function
 Mechanical ventilation [n (%)] 56 (77.8 %) 16 (76.2 %) 1.0
 FiO2 0.35 (0.26, 0.47) 0.40 (0.30, 0.50) 0.15
 PaO2 (kPa) 10 (9, 11) 10 (9, 11) 0.95
 PaO2/FiO2 ratio 29 (20, 42) 26 (18, 35) 0.31
 PaCO2 (kPa) 4.8 (4.3, 5.4) 4.5 (4.3, 5.0) 0.12
Metabolic
 pH 7.4 (7.3, 7.4) 7.4 (7.3, 7.4) 0.64
 Base excess (mmol/L) 0.2 (−2.4, 2.8) −0.3 (−4.1, 1.0) 0.18
 Lactate (mmol/L) 1.6 (1.2, 2.6) 2.1 (1.2, 2.8) 0.50
Inflammatory response
 SIRS [n (%)] 52 (72.2 %) 14 (66.7 %) 0.60
 SIRS + suspected or confirmed infection [n (%)] 38 (52.8 %) 13 (61.9 %) 0.62
 White cell count (×109/L) 11 (8, 15) 10 (8, 13) 0.45
 C‑reactive protein (mg/dL) 74 (26, 181) 45 (15, 193) 0.56
Plasma biomarkers levels on inclusion
 Endostatin (ng/mL) 31 (23, 40) 42 (35, 54) 0.002
 Cystatin C (mg/dL) 0.75 (0.64, 1.00) 1.10 (0.82, 1.40) 0.02
 NGAL (ng/mL) 97 (66, 149) 133 (67, 180) 0.29
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AKI or CKD on study inception. However, the majority 
of our critically ill patients had SIRS or sepsis at inclu-
sion, which could be expected to affect endostatin levels 
in the same way it affects other biomarkers of AKI [15, 
16]. For example, NGAL, which is released both by kid-
ney epithelial cells and by activated neutrophils during 
systemic inflammation [17, 18], was elevated in our sep-
tic subgroup.
Similarly, collagen turnover is enhanced in sepsis, and 
this is reflected in elevated levels of circulating collagen 
degradation products [19]. Theoretically, matrix break-
down in non-renal tissues during sepsis could contribute 
to circulating endostatin levels. However, when compar-
ing septic and non-septic patients we observed similar 
levels in both groups, suggesting minimal release of non-
renal endostatin into the circulation in our patients.
Kidney extracellular matrix remodeling and angiogen-
esis appear to play an important role in the initiation, 
maintenance and progression of AKI [20, 21]. In experi-
mental animal models of AKI, endothelial activation 
and damage lead to both disruption of renal endothelial 
cell integrity and endothelial matrix breakdown [3, 22]. 
This appears to be mediated via proteinase activation 
and cleavage of matrix collagens and leads to vascular 
leak, renal parenchymal edema and organ dysfunction 
[23]. Similar mechanisms have been demonstrated to 
contribute to the development of CKD [21]. Our find-
ing that elevated circulating endostatin levels preceded 
AKI, as evident by a subsequent rise in creatinine, and 
remained elevated until such AKI was established sup-
ports the pathophysiological role of matrix breakdown 
and endothelial injury/dysfunction in AKI development. 
Additionally, we observed a slight increase in median 
endostatin levels in non-AKI patients reaching the opti-
mal AKI predictive cutoff level (37  ng/mL) on day 3 
(Fig.  2). Whether this delayed endostatin rise was trig-
gered by some degree of “subclinical” AKI, by non-
renal matrix breakdown or by both remains, however, 
uncertain.
Finally, as endostatin is a middle-sized molecule 
(20  kDa), which is freely filtered by the glomeruli, its 
plasma concentration may reflect glomerular filtration 
rate (GFR). In keeping with this hypothesis, an inverse 
correlation between plasma endostatin and GFR has 
indeed been established [5, 13]. Hence, impaired clear-
ance of middle-sized molecules but not yet affecting 
smaller molecules such as creatinine (0.11  kDa) could 
potentially explain the observed early rise in endostatin. 
However, cystatin C (13  kDa) and NGAL (25  kDa) are 
both middle-sized molecules, but their patterns of release 
in our cohort differed from that of endostatin, and nei-
ther improved predictive modeling. In their aggregate, 
these observations suggest that increased production/
release rather than impaired clearance of endostatin 
likely caused its early rise in plasma.
Implications of study findings
Our findings may have implications for patient manage-
ment. They support the emerging view that microcircula-
tory dysfunction is a key step in the establishment of AKI 
[24]. Endostatin may, in conjunction with other biomark-
ers of renal stress or injury, be a useful biomarker of the 
natural history of AKI and the transition from AKI to 
CKD. Within the limitations of this small cohort, our data 
suggest that elevated plasma endostatin may be an earlier 
and more specific signal of kidney stress or injury, espe-
cially in conjunction with clinical risk factors, than two 
previously proposed AKI markers: NGAL and cystatin C. 
Whether this signal is a useful tool to detect patients “at 
risk” of AKI, however, needs to be assessed in combina-
tion with validated clinical risk models in independent 
cohorts of critically ill patients. In particular, biomarker 
performance may be different in patients with sepsis. In 
fact, in a recent cohort of 112 septic patients, the ability 
to predict AKI within 24 h was fair using plasma cysta-
tin C [AUC 0.737 (95 % CI 0.633–0.841)] and good using 
plasma NGAL [AUC 0.830 (95 % CI 0.741–0.919)] [25].
In contrast, cystatin C and NGAL demonstrated 
poor predictive performance in our study. This may be 
explained by the fact that we included both septic and 
non-septic patients and that we measured the occurrence 
of AKI up to 72 h after biomarker measurement. Based 
on these conflicting findings, future studies need to com-




















Fig. 2 Plasma endostatin levels during the first five study days in AKI 
and non‑AKI patients. Values are median and interquartile range. P 
value is for the repeated‑measure ANOVA between groups
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cystatin C and NGAL in cohorts of septic patients and 
within different time-points of AKI diagnosis.
Promising therapies against acute renal microcircu-
latory changes have been demonstrated in animal AKI 
models but failed to improve kidney function or other 
patient-centered outcomes in clinical studies [24, 26]. 
Future studies should explore the role of plasma endosta-
tin as a trigger of therapies targeting the renal microcir-
culation. Finally, endostatin may be particularly attractive 
in conjunction with novel imaging techniques of the 
renal microcirculation such as contrast-enhanced ultra-
sound [27, 28] and blood-oxygen level-dependent con-
trast imaging [29] to monitor therapeutic effects.
Strengths and limitations
Our study has several strengths. It includes a well-defined 
cohort of critically ill patients without renal disease on 
ICU admission, yet at significant risk of developing AKI. 
Secondly, detailed data collection allowed us to develop 
a risk model using meaningful clinical and physiologi-
cal parameters and to compare endostatin to established 
renal biomarkers like cystatin C and NGAL. Thirdly, data 
were prospectively collected and are therefore unlikely to 
be biased. Finally, despite a limited number of AKI cases, 
the added value of endostatin in risk prediction was con-
sistently found in multiple analyses, which increases the 
robustness of our findings.
Our study has, however, limitations. It was a single-
center study, which limits the generalizability of the study 
findings. It was, however, performed in a tertiary hospital 
suggesting some degree of external validity to similar hos-
pitals in the developed world. CKD patients were excluded 
and the value of endostatin to predict acute-on-chronic 
kidney injury cannot be extrapolated from our findings. Ill-
ness severity (APACHE II) was generally low in our cohort. 
This was, however, expected since we excluded patients 
admitted with AKI, a population well known to be more 
severely ill. Furthermore, given our small study sample the 
robustness of our clinical risk model may be limited. How-
ever, our model includes clinically relevant and established 
risk factors (early oliguria, illness severity and age) of AKI. 
Additionally, we developed and validated the clinical risk 
model on the same cohort. This approach may inflate its 
predictive value. However, such potential inflation applied 
to all other biomarkers as well, and yet the addition of 
Fig. 3 Plasma endostatin (a), cystatin C (b) and NGAL (c) at study 
inclusion in patients with and without sepsis
Table 3 Values for prediction of AKI within 72 h
AUC area under the receiver operating characteristics curve, NRI net 
reclassification improvement, IDI integrated discrimination improvement
a P values for AUC assess the difference from 0.5
Statistic Estimate (95 % CI) P valuea
AUC endostatin alone 0.726 (0.603 to 0.848) <0.001
AUC cystatin C alone 0.674 (0.535 to 0.812) 0.01
AUC NGAL alone 0.577 (0.430 to 0.723) 0.22
AUC early oliguria 0.618 (0.509 to 0.727) 0.04
AUC clinical model 0.759 (0.646 to 0.872) <0.001
AUC clinical model + endostatin 0.839 (0.752 to 0.925) <0.001
AUC clinical model + cystatin C 0.776 (0.662 to 0.890) <0.001
AUC clinical model + NGAL 0.766 (0.657 to 0.874) <0.001
NRI (endostatin) 0.268 (0.010 to 0.526) 0.04
IDI (endostatin) 0.073 (0.038 to 0.142) 0.04
NRI (cystatin C) 0.06 (−0.16 to 0.28) 0.63
IDI (cystatin C) 0.012 (−0.013 to 0.037) 0.34
NRI (NGAL) 0.035 (−0.15 to 0.22) 0.71
IDI (NGAL) 0.0061 (−0.013 to 0.025) 0.53
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endostatin proved superior and significantly improved risk 
prediction. Finally, plasma samples were collected between 
2007 and 2010 and analyzed for endostatin and NGAL 
during 2013. Such an extended storage period may impact 
biomarker concentrations. However, samples were stored 
at −80  °C, which preserve NGAL concentrations during 
long-term storage [30]. It is unlikely that identical storage 
conditions would affect endostatin levels differently.
Conclusions
Our results suggest that plasma endostatin may be a fair 
predictor of AKI developing within 72 h of ICU admis-
sion in patients without preexisting renal disease. Com-
bining endostatin with clinical variables may further 
enhance AKI risk prediction in such patients. In addition, 
within the limitations of an exploratory investigation, 
our findings suggest that endostatin may outperform two 
previously proposed AKI markers, cystatin C and NGAL. 
Our results provide the basis for further evaluation of 
endostatin as a biomarker of early AKI in independent 
cohorts of critically ill patients.
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